N-acetyl cysteine study for people with multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether N-acetyl cysteine (a supplement-like medicine) changes body and brain function in people with multiple sclerosis. It may help researchers understand how it affects brain chemistry and activity using special brain imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting or progressive multiple sclerosis
- You will not start a new MS medicine during the study, or your MS medicine is stable (like interferon, glatiramer, dimethyl fumarate, or teriflunomide)
- You are at least 18 and can walk independently (not wheelchair-bound or bed-ridden)
- You can travel to and complete all study visits and scans in the greater Philadelphia area
- If you can become pregnant: you agree to a negative pregnancy test and effective birth control during the study; if your partner can become pregnant, you also use effective contraception
- You can complete memory testing and brain scans (and you do not have severe anxiety about enclosed spaces)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses a special PET scan and an MRI to look at nerve-related inflammation in people with multiple sclerosis (MS). The goal is to see whether this scan can detect MS-related changes, which could improve how MS is studied in the future.
This early study uses special brain scans (PET and MRI) to measure “synapse density” (how many connection points brain cells have) in people with multiple sclerosis (MS). It may help researchers understand MS biology and improve future treatments.
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
This study uses brain scans to look for hidden inflammation in people with multiple sclerosis who have not yet started a strong treatment. It aims to understand how this inflammation affects the disease and to help guide future therapies.
This study tests a new imaging method using a special substance called hyperpolarized 13C pyruvate to see how it can help understand multiple sclerosis. You may join if you have relapsing-remitting MS, have not used disease-modifying treatments in the past two years, and are planning to start anti-CD20 therapy.
This trial uses brain stimulation and MRI to study how the brain controls muscle movement in people with relapsing-remitting MS. Researchers want to understand changes in brain 'inhibition' (a natural stopping signal) that might affect walking or thinking.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.